Miniatura

Fitxers

733239.pdf (4.74 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-04-10

Llicència de publicació

cc-by-nc-nd (c) Sanchez Moral, Lidia et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/196960

Macrophage Cd5l is a target for cancer immunotherapy

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.ebiom.2023.104555

Resum

Background Reprogramming of immunosuppressive tumor-associated macrophages (TAMs) presents an attractive therapeutic strategy in cancer. The aim of this study was to explore the role of macrophage CD5L protein in TAM activity and assess its potential as a therapeutic target. Methods Monoclonal antibodies (mAbs) against recombinant CD5L were raised by subcutaneous immunization of BALB/c mice. Peripheral blood monocytes were isolated from healthy donors and stimulated with IFN/LPS, IL4, IL10, and conditioned medium (CM) from different cancer cell lines in the presence of anti-CD5L mAb or controls. Subsequently, phenotypic markers, including CD5L, were quantified by flow cytometry, IF and RT-qPCR. Macrophage CD5L protein expression was studied in 55 human papillary lung adenocarcinoma (PAC) samples by IHC and IF. Anti-CD5L mAb and isotype control were administered intraperitoneally into a syngeneic Lewis Lung Carcinoma mouse model and tumor growth was measured. Tumor microenvironment (TME) changes were determined by flow cytometry, IHC, IF, Luminex, RNAseq and RT-qPCR. Findings Cancer cell lines CM induced an immunosuppressive phenotype (increase in CD163, CD206, MERTK, VEGF and CD5L) in cultured macrophages. Accordingly, high TAM expression of CD5L in PAC was associated with poor patient outcome (Log-rank (Mantel-Cox) test p = 0.02). We raised a new anti-CD5L mAb that blocked the immunosuppressive phenotype of macrophages in vitro. Its administration in vivo inhibited tumor progression of lung cancer by altering the intratumoral myeloid cell population profile and CD4+ T-cell exhaustion phenotype, thereby significantly modifying the TME and increasing the inflammatory milieu. Interpretation CD5L protein plays a key function in modulating the activity of macrophages and their interactions within the TME, which supports its role as a therapeutic target in cancer immunotherapy.

Matèries

Macròfags, Immunoteràpia

Matèries (anglès)

Macrophages, Immunotheraphy

Citació

Col·leccions

Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)

Citació

SANCHEZ MORAL, Lidia, PAUL, Tony, MARTORI, Clara, FONT DÍAZ, Joan, SANJURJO, Lucía, ARAN, Gemma, TÉLLEZ, Érica, BLANCO, Julià, CARRILLO MOLINA, Jorge, ITO, Masaoki, TUTTOLOMONDO, Martina, DITZEL, Henrik j., FUMAGALLI, Caterina, TAPIA, Gustavo, SIDOROVA, Julia, MASNOU, Helena, FERNÁNDEZ SANMARTÍN, Marco-antonio, LOZANO SALVATELLA, Juan josé, VILAPLANA, Cristina, RODRIGUEZ CORTÉS, Alhelí, ARMENGOL, Carolina, VALLEDOR FERNÁNDEZ, Annabel, KREMER, Leonor, SARRIAS, Maria rosa. Macrophage Cd5l is a target for cancer immunotherapy. _EBioMedicine_. 2023. Vol. 91, núm. 104555. [consulta: 24 de gener de 2026]. ISSN: 2352-3964. [Disponible a: https://hdl.handle.net/2445/196960]

Exportar metadades

JSON - METS

Compartir registre